Valneva SE (VALN) Other Non-Current Assets (2020 - 2026)
Valneva SE's (VALN) quarterly Other Non-Current Assets came in at $8.9 million in Q1 2026, up 1.0% year-on-year from $8.8 million in Q1 2025, and little changed quarter-over-quarter from $8.8 million in Q4 2025.
Valneva SE (VALN) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Valneva SE has disclosed Other Non-Current Assets across 7 years of filings, most recently posting $8.9 million for Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $8.9 million, up 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.9 million (up 1.0% YoY), and the FY2025 annual result was $8.8 million, up 2.82% from the prior year.
- Other Non-Current Assets came in at $8.9 million for Q1 2026 at Valneva SE, roughly flat from $8.8 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $9.8 million in Q2 2025 to a low of $50505.2 in Q1 2022.
- The 5-year median for Other Non-Current Assets is $8.7 million (2025), against an average of $7.3 million.
- Across the five-year window, Other Non-Current Assets soared 18403.6% in 2022 and decreased 7.77% in 2025, its largest moves.
- Valneva SE's Other Non-Current Assets stood at $8.5 million in 2022, then climbed by 7.89% to $9.1 million in 2023, then declined by 5.94% to $8.6 million in 2024, then advanced by 2.82% to $8.8 million in 2025, then rose by 0.4% to $8.9 million in 2026.
- The last three Other Non-Current Assets figures came in at $8.9 million (Q1 2026), $8.8 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 8.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.87 Mn |
| Dec 31, 2025 | 8.84 Mn |
| Sep 30, 2025 | 8.68 Mn |
| Jun 30, 2025 | 9.77 Mn |
| Mar 31, 2025 | 8.78 Mn |
| Dec 31, 2024 | 8.59 Mn |
| Sep 30, 2024 | 8.30 Mn |
| Jun 30, 2024 | 9.74 Mn |
| Mar 31, 2024 | 9.52 Mn |
| Dec 31, 2023 | 9.13 Mn |
| Dec 31, 2022 | 8.47 Mn |
| Sep 30, 2022 | 2.98 Mn |
| Jun 30, 2022 | 51,218.72 |
| Mar 31, 2022 | 50,505.20 |
| Dec 31, 2021 | 45,758.84 |
| Sep 30, 2021 | 50,709.35 |
| Jun 30, 2021 | 50,579.40 |
| Mar 31, 2021 | 51,868.15 |
| Dec 31, 2020 | 48,883.88 |